How to Treat Small Cell Lung Cancer (SCLC) – Treatment Algorithm with Dr. Jacob Sands

Small cell lung cancer treatment has evolved significantly, shifting toward immunotherapy and targeted maintenance strategies. In limited-stage disease, concurrent chemoradiation followed by two years of durvalumab is the new standard of care, yielding substantial improvements in overall survival. For extensive-stage disease, the IMforte regimen—combining chemotherapy and atezolizumab induction with atezolizumab and lurbinectedin maintenance—has emerged as the preferred approach. Additionally, tarlatamab represents a breakthrough in second-line treatment, demonstrating superior overall survival compared to traditional chemotherapy. While prophylactic cranial irradiation remains debated, MRI surveillance is increasingly favored to preserve quality of life. Dr. Jacob Sands, a thoracic medical oncologist from Dana-Farber Cancer Institute, highlights the importance of clinical trial participation and the potential of agents like trilaciclib to mitigate treatment-related toxicities, ultimately aiming to improve long-term outcomes for patients facing this aggressive malignancy.